AdaptHealth (AHCO) Insider Gregory Belinfanti Buys 18,999 Shares

AdaptHealth Insider Activity Brings New Purchases

AdaptHealth Corp. (NasdaqCM: AHCO) saw a wave of insider buying on June 24, 2026, when Gregory Belinfanti and several colleagues each picked up 18,999 shares of the company. These transactions add to a series of insider purchases reported on the same day by other associated individuals, reflecting continued internal participation in the medical equipment provider.

More Insiders Step Up Stock Purchases

The late-June purchasing flurry involved multiple individuals making identical transactions. Alongside Gregory Belinfanti, insiders Terence Connors, Theodore Lundberg, Bradley Coppens, Susan Weaver, and Williams David Solomon III each acquired 18,999 shares of AdaptHealth Corp. on June 24, 2026. These disclosures show multiple stakeholders taking on identical share amounts on the exact same date.

AdaptHealth Stock Performance and Range

Shares of AdaptHealth recently traded at $10.29, holding a position well above the 52-week low of $5.21 and below the 52-week high of $13.43. The stock's 50-day moving average sits at $7.41, while the 200-day moving average rests at $9.79. With a market capitalization of roughly $767.1 million, the medical device firm operates with a beta of 1.39, pointing to higher volatility than the broader market.

Recent Earnings Context

AdaptHealth posted $3.36 billion in revenue over the last reported period, alongside a revenue growth rate of 12.7%. The company reported a net margin of -6.7% and a return on equity of -15.2%, with earnings per share at -$1.71. The next corporate earnings release is scheduled for November 3, 2026.

Wall Street Analyst Views on AHCO

Analyst sentiment around the company includes mixed price target adjustments alongside positive ratings. On September 17, 2026, Baird maintained its Outperform rating with a $9.0 price target. Earlier in August, UBS maintained a Buy rating while lowering its target from $14.0 to $10.0, and RBC Capital kept an Outperform rating while reducing its target from $15.0 to $8.0. Truist Securities maintained a Buy rating with a $9.0 target on August 5, 2026, following an upgrade to Buy from Jefferies in July with a $13.0 target. Overall, the stock carries a strong buy recommendation across seven analyst opinions, with a mean price target of $9.0.

Inside the Business Operations

AdaptHealth Corp. operates out of Conshohocken, Pennsylvania, distributing home medical equipment, supplies, and related services across the United States. The company provides sleep therapy equipment for sleep apnea, respiratory and chronic therapy services, and diabetes management devices such as continuous glucose monitors and insulin pumps. Serving patients discharged from acute care alongside Medicare and Medicaid beneficiaries, the firm employs approximately 10,900 people.

What to Watch at AdaptHealth Corp.

Investors tracking AdaptHealth will look toward the upcoming earnings report on November 3, 2026, for updated financial metrics. Future SEC filings will provide further clarity on how internal stakeholders manage their holdings, though insider transactions remain backward-looking indicators and do not serve as direct investment signals.